EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of Posttherapy 4- and 24-Hour [ 177 Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer

Mina Swiha, Sarennya Pathmanandavel, Nathan Papa, Zahra Sabahi, Sherrington Li, Alex Zheng, Sobia Khan, Maria Ayers, Shikha Sharma, Megan Crumbaker, Andrew Nguyen, Lyn Chan und 2 weitere

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.124.267606 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Mina Swiha und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia; mina.swiha@gmail.com. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Positron Emission Tomography Computed Tomography, Single Photon Emission Computed Tomography Computed Tomography, Lutetium. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

[177Lu]Lu-prostate-specific membrane antigen (PSMA) is an effective treatment for metastatic castration-resistant prostate cancer (mCRPC). [177Lu]Lu-PSMA SPECT/CT 24 h after injection has shown potential as a response biomarker for [177Lu]Lu-PSMA therapy but is not convenient for patients. This study investigated 4-h [177Lu]Lu-PSMA SPECT/CT as an alternative to 24-h [177Lu]Lu-PSMA SPECT/CT for evaluation of treatment response.

Methods

This prospective analysis enrolled 23 patients diagnosed with mCRPC commencing [177Lu]Lu-PSMA-I&T therapy. Two patients were excluded because of incomplete imaging data. Posttherapy SPECT/CT was performed at 4 and 24 h after the first dose and 4 h after the second dose. Baseline [68Ga]Ga-PSMA-11 PET/CT and 4- and 24-h [177Lu]Lu-PSMA SPECT/CT were analyzed both visually and semiquantitatively. Bland-Altman plots assessed agreement of semiquantitative parameters from the 4- and 24-h scans. Quantitative assessment of the change in the total tumor volume (TTV) on the 4-h [177Lu]Lu-PSMA SPECT/CT after the first and second doses was correlated to patient outcomes.

Results

All patients had mCRPC previously treated with an androgen receptor pathway inhibitor, and 11 (52%) received prior taxane chemotherapy. Median age was 78 y, and median prostate-specific antigen level was 54 ng/mL. On visual analysis, disease distribution was unchanged among the 3 imaging methods. Eleven patients (52%) had a median of 1 lesion not identified on 4-h [177Lu]Lu-PSMA SPECT/CT compared with 24-h [177Lu]Lu-PSMA SPECT/CT. All missed lesions on the 4-h [177Lu]Lu SPECT/CT were smaller than 2 cm. Mean differences and agreement between 4- and 24-h SPECT/CT quantitative parameters were within acceptable bounds for lesion number, SUVmax, and SUVmean, with higher variation observed for TTV. The change in TTV between dose 1 and 2 [177Lu]Lu-PSMA SPECT/CT predicted prostate-specific antigen progression-free survival. Conclusion: [177Lu]Lu-PSMA SPECT/CT at 4 h after injection appears a promising alternative to 24-h [177Lu]Lu-PSMA SPECT/CT for treatment response assessment, with improved patient convenience.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantPositron Emission Tomography Computed TomographySingle Photon Emission Computed Tomography Computed TomographyLutetiumHumansMaleAgedMiddle AgedNeoplasm MetastasisAged, 80 and overTreatment OutcomeTime FactorsGlutamate Carboxypeptidase IIProspective StudiesDipeptidesAntigens, SurfaceRadiopharmaceuticalsRadioisotopesProstate-Specific Antigen

Stichwörter der Autor:innen

PSMA PET[177Lu]Lu-PSMA[177Lu]Lu-PSMA SPECTprostate cancer

Substanzen

LutetiumGlutamate Carboxypeptidase IIPluvictoDipeptidesLutetium-177Antigens, SurfaceFOLH1 protein, humanRadiopharmaceuticalsRadioisotopesProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia; mina.swiha@gmail.com.
  • Molecular Imaging and Theranostics Division, Department of Medical Imaging, University of Western Ontario, London, Ontario, Canada.
  • Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.
  • Garvan Institute of Medical Research, Sydney, New South Wales, Australia; and.
  • St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.

Zitieren

APA

Swiha, M., Pathmanandavel, S., Papa, N., Sabahi, Z., Li, S., Zheng, A., Khan, S., Ayers, M., Sharma, S., Crumbaker, M., Nguyen, A., Chan, L., Ayati, N., & Emmett, L. (2024). Comparison of Posttherapy 4- and 24-Hour [ 177 Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.267606

Vancouver

Swiha M, Pathmanandavel S, Papa N, Sabahi Z, Li S, Zheng A, et al. Comparison of Posttherapy 4- and 24-Hour [ 177 Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.124.267606

BibTeX
@article{Swiha2024,
  author = {Swiha, Mina and Pathmanandavel, Sarennya and Papa, Nathan and Sabahi, Zahra and Li, Sherrington and Zheng, Alex and Khan, Sobia and Ayers, Maria and Sharma, Shikha and Crumbaker, Megan and Nguyen, Andrew and Chan, Lyn and Ayati, Narjess and Emmett, Louise},
  title = {Comparison of Posttherapy 4- and 24-Hour [ 177 Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.124.267606}
}
Kostenlos starten →